Bayer & Monsanto deal worries skeptics, investors

Global Business

It is the biggest cash takeover in history, but it’s shrouded in controversy. Investors have shown some skepticism that worrying this $66 billion deal is bigger than it’s true worth.

It is the biggest cash takeover in history, but it’s shrouded in controversy.

The mega-merger between German chemical giant Bayer and U.S. genetically modified seed firm Monsanto is causing major concern to campaign groups.

CCTV America’s Guy Henderson reports from Berlin.
Follow Guy Henderson on Twitter @guyhendersonde

GM is common in U.S. seed-making company Monsanto’s home turf where proponents argue such technology could help solve world hunger. But it’s rare in Europe where many question its ethics.

Investors have shown some skepticism that worrying this $66 billion deal is bigger than it’s true worth.

Bayer has specifically said it won’t bring GM to Europe, but many don’t believe them. Ultimately, this is a rift that goes beyond one deal and in fact dates back decades: pitting those who see such technology as a vital life-saver and profit-maker and those who say it’s messing with nature.